COVID-19 total Ab - RAPID TEST

3 minutes - Fast result 
2 steps - Easy to use 
LIS Connectivity - Data management
 
FREND COVID-19 total Ab
The FREND COVID-19 total Ab is a point-of-care testing (POCT) which can be used to 
check whether patients have developed immune responses to SARS-CoV-2 using human serum or plasma. For COVID-19 IgG/IgM Duo, its detection is based on a fluorescent immunoassay showing QUALITATIVE result. Originally, the FREND System is a quantitative assay and it can be used to detect additional markers for additional studies.
 
Clinical Performance Evaluation
The total of 59 clinical specimens (43 positive and 16 negative) confirmed with RT-PCR were tested with the FREND™ COVID-19 IgG/IgM Duo. It shows 93% PPA (Positive Percent Agreement) and 100% NPA (Negative Percent Agreement) 
 
For specimens collected after day 8 from the onset of symptoms, the FRENDTM COVID-19 IgG/IgM 
Duo shows 100% PPA. Therefore, it is recommended to test specimens at a minimum of day 8. A similar tendency was found in another cohort study.
 
Why serological test is necessary?
Molecular diagnostic kit such as RT-PCR is very useful in detecting the presence of viral genes. 
However, this cannot tell whether the person has developed an immune response to SARS-CoV-2. 
Therefore, serological test using blood samples is required to detect whether symptoms 
developed from infection or the infection was asymptomatic (Centers for Disease Control and Prevention is also developing its own serological test using IgG and IgM).
 
-Serological test is required to check the presence of immune response to SARS-CoV-2. 
-Useful sources to distinguish symptomatic and asymptomatic patients.
 
After the onset of symptoms, the sensitivity of the positive PCR results showed higher than 90% from day 1 to day 3. However, it decreased below 80% and 50% on day 6 and day 14, respectively. The combination of PCR with serological tests increased the positive sensitivity by 47%.
 
Using FRENDTM System for Extension Study
Most of the rapid kits only offer tests on Serological Diagnostic Kits using IgG and IgM. 
However, the FRENDTM System can also be used to manage and assess COVID-19 patient in secondary infection or comorbidities that could follow using the additional markers, D-dimer, Troponin I, PCT, IL-6, and CRP (C-reactive protein) through QUANTITATIVE detection.

Laboratory Information System Connectivity
In the event of a pandemic, the management of a vast amount of clinical results is important. 
However,   many laboratories face the challenge of arranging essential information effectively. The FREND System which is LIS compatible provide following features:
Paperless
Time-saving
Automatic Data Transfer & Collect
Convenient Data Management
Can Help Monitoring (serosurveillance)